TP53 and cancer: Given that the SK-N-SH cell line did not demonstrate a sustained increase in caspase activity or an accumulation of p53 protein with combination treatment (Fig. 5A–C), a different mechanism of action may contribute to combination therapy’s anti-cancer activity in non-MYCN-amplifying cell lines.